Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinson’s Disease Dementia

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias. Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB) over 24 weeks using caregiver-rated QOL-Alzheimer’s disease (AD) in domains according to the WHO’s classification of health. Results: Baseline QOL shows lower ratings for body functions over environmental factors in DLB/PDD. Treatment with memantine significantly improves life as a whole compared to placebo and improves total QOL, body function and structure. Conclusion: This study shows that memantine improves QOL in Lewy body dementias. We also demonstrate important QOL patterns which can be used in clinical practice.

Related collections

Most cited references 19

Record: found
Abstract: found
Article: not found

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.

C Lippa, J Duda, M. Grossman … (2007)

For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). This article addresses the relationship between DLB, PD, and PD with dementia (PDD). The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these disorders of alpha-synuclein metabolism. We concluded that the differing temporal sequence of symptoms and clinical features of PDD and DLB justify distinguishing these disorders. However, a single Lewy body disorder model was deemed more useful for studying disease pathogenesis because abnormal neuronal alpha-synuclein inclusions are the defining pathologic process common to both PDD and DLB. There was consensus that improved understanding of the pathobiology of alpha-synuclein should be a major focus of efforts to develop new disease-modifying therapies for these disorders. The group agreed on four important priorities: 1) continued communication between experts who specialize in PDD or DLB; 2) initiation of prospective validation studies with autopsy confirmation of DLB and PDD; 3) development of practical biomarkers for alpha-synuclein pathologies; 4) accelerated efforts to find more effective treatments for these diseases.

0 comments Cited 131 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

The clinical significance of adaptation to changing health: a meta-analysis of response shift.

Nicholas Repucci, Rita Bode, Mirjam Sprangers … (2006)

When individuals experience changes in their health states, they may alter their internal standards, values, or conceptualization of quality of life (QOL). Such 'response shifts' can affect or distort QOL outcome measurement, which is of particular concern when evaluating medical or psychosocial interventions. Although clinicians and researchers acknowledge the occurrence of response shifts, little is known about the magnitude and clinical significance of those effects. To fill this gap in knowledge about response shift phenomena, we performed a meta-analysis on published QOL articles on response shift. Extensive literature searches and multiple contacts with researchers yielded a collection of 494 articles for potential reviewing. We retained only published longitudinal studies that measured response shift, resulting in 26, of which 19 reported the requisite data for computing an effect size (ES). We calculated and compared the ESs for each study with regard to potential moderator variables: the QOL domains measured, disease group investigated, sample size, and response shift method used. We rated studies for quality to allow ES weighting. When we examined ES absolute values, we found that ES magnitude was small, with the largest ESs detected for fatigue, followed by global QOL, physical role limitation, psychological well-being, and pain (mean absolute value(ES(weighted)) = 0.32, 0.30, 0.24, 0.12, and 0.08, respectively). ESs varied considerably in direction. Aggregating raw ES scores over all studies led to positive and negative values canceling each other out (mean directional ES(weighted) = 0.17, 0.02, -0.01, 0.06, and 0.02, respectively). We found little evidence of an effect for the moderator variables examined. A definitive conclusion on the clinical significance of response shift cannot currently be drawn from existing studies. For a number of reasons, ES estimates were primarily based on then-test results, a method that is not without criticism, such as its susceptibility to recall bias. We recommend a standardized approach for reporting results of future response shift research to advance the field and to facilitate interpretation and comparisons across studies.

0 comments Cited 109 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria

Dag Aarsland, Arvid Rongve, Sabine Piepenstock Nore … (2008)

Objective: To find the proportion of dementia with Lewy bodies (DLB) in a referral cohort of patients with a first-time diagnosis of mild dementia. Background: The proportion of DLB among the dementia sufferers is not known and the clinical consensus criteria have low sensitivity. We employed the revised DLB criteria to study the proportion with DLB in a community sample of patients with mild dementia. Methods: From March 2005 to March 2007, we included 196 patients from referrals to all geriatric medicine, old age psychiatry and neurology outpatient clinics in Rogaland and Hordaland counties in Western Norway. Standardized clinical instruments and diagnostic criteria were employed. Results: 65% had Alzheimer dementia, 20% DLB (16% probable DLB), 5.6% vascular dementia, 5.6% Parkinson disease with dementia, 2.0% frontotemporal dementia and 1.5% alcoholic dementia. There were no significant differences in the proportion with DLB according to age bands and dementia severity groups. The revised criteria for a clinical diagnosis of DLB increased the proportion of probable DLB by 25% compared to the previous criteria. Conclusion: DLB is common in patients with mild dementia, and is the second most common type of dementia. The introduction of new clinical criteria for DLB leads to an increase in the proportion diagnosed with probable DLB.

0 comments Cited 81 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (publisher-id): DEM

Journal ID (nlm-ta): Dement Geriatr Cogn Disord

Journal ID (doi): 10.1159/issn.1420-8008

Title: Dementia and Geriatric Cognitive Disorders

Publisher: S. Karger AG

ISSN (Print): 1420-8008

ISSN (Electronic): 1421-9824

Publication date Subscription-year: 2011

Publication date (Print): February 2012

Publication date (Electronic): 25 November 2011

Volume: 32

Issue: 4

Pages: 227-234

Affiliations

^aClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, and ^bKarolinska Institute, Huddinge, Sweden; ^cResearch Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, ^dThe Norwegian Centre for Dementia Research, University Hospital Ullevaal and ^eFaculty of Medicine, University of Oslo, Oslo, and ^fPsychiatric Division, Section for Geriatric Psychiatry, Stavanger University Hospital, Stavanger, Norway

Author notes

*Victoria Larsson, Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö University Hospital, SE–205 02 Malmö (Sweden), Tel. +46 4479 5498 5158, E-Mail v.larsson@ucl.ac.uk

Article

Publisher ID: 334523 Other ID: Dement Geriatr Cogn Disord 2011;32:227–234

DOI: 10.1159/000334523

PubMed ID: 22122992

SO-VID: f0240b19-8ff2-4cad-aeca-fa87bb05fc6a

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date accepted : 17 October 2011

Page count

Figures: 5, Tables: 3, Pages: 8

Comments

Comment on this article

scite_

Cited by 15

See all cited by

Most referenced authors 532

See all reference authors

- Version 1

Call for Papers: Sex and Gender in Neurodegenerative Diseases

Submit here before September 30, 2024

Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinson’s Disease Dementia

Read this article at

Abstract

Related collections

Karger: Neurology and Neuroscience

Most cited references 19

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.

The clinical significance of adaptation to changing health: a meta-analysis of response shift.

Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria

Author and article information

Journal

Affiliations

Author notes

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 854

Cited by 15

Most referenced authors 532